Editas Medicine, Inc. (EDIT)
3.00
-0.11
(-3.54%)
USD |
NASDAQ |
Aug 24, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Enterprise Value : 320.20M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 320.20M |
| August 21, 2026 | 337.09M |
| August 20, 2026 | 310.98M |
| August 19, 2026 | 358.58M |
| August 18, 2026 | 301.77M |
| August 17, 2026 | 295.63M |
| August 14, 2026 | 292.56M |
| August 13, 2026 | 291.03M |
| August 12, 2026 | 295.63M |
| August 11, 2026 | 312.52M |
| August 10, 2026 | 291.03M |
| August 07, 2026 | 301.77M |
| August 06, 2026 | 304.84M |
| August 05, 2026 | 281.81M |
| August 04, 2026 | 284.88M |
| August 03, 2026 | 266.46M |
| July 31, 2026 | 255.71M |
| July 30, 2026 | 272.60M |
| July 29, 2026 | 258.78M |
| July 28, 2026 | 261.86M |
| July 27, 2026 | 271.07M |
| July 24, 2026 | 258.78M |
| July 23, 2026 | 278.74M |
| July 22, 2026 | 286.42M |
| July 21, 2026 | 303.31M |
| Date | Value |
|---|---|
| July 20, 2026 | 301.77M |
| July 17, 2026 | 317.13M |
| July 16, 2026 | 301.77M |
| July 15, 2026 | 326.34M |
| July 14, 2026 | 344.76M |
| July 13, 2026 | 344.76M |
| July 10, 2026 | 360.11M |
| July 09, 2026 | 366.26M |
| July 08, 2026 | 423.06M |
| July 07, 2026 | 435.34M |
| July 06, 2026 | 419.99M |
| July 02, 2026 | 419.99M |
| July 01, 2026 | 363.19M |
| June 30, 2026 | 357.04M |
| June 29, 2026 | 261.50M |
| June 26, 2026 | 227.25M |
| June 25, 2026 | 216.48M |
| June 24, 2026 | 222.35M |
| June 23, 2026 | 218.44M |
| June 22, 2026 | 222.35M |
| June 18, 2026 | 211.59M |
| June 17, 2026 | 197.89M |
| June 16, 2026 | 179.29M |
| June 15, 2026 | 189.08M |
| June 12, 2026 | 192.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Geron Corp. | 925.59M |
| Novavax, Inc. | 1.038B |
| Recursion Pharmaceuticals, Inc. | 1.251B |
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.23M |
| Revenue (Quarterly) | 11.89M |
| Total Expenses (Quarterly) | 30.12M |
| EPS Diluted (Quarterly) | -0.1528 |
| Gross Profit Margin (Quarterly) | 96.50% |
| Profit Margin (Quarterly) | -153.3% |
| Earnings Yield | -24.82% |
| Normalized Earnings Yield | -26.59 |